PI: H. Lee Sweeney, PhD, University of Florida
CO-PI: Melissa Spencer, PhD, UCLA
From its inception, the main goal of this Wellstone MDCRC has been to promote the translation of promising emerging therapeutic targets into clinical trials for muscular dystrophy patients. As such, there has been one project devoted to the discovery of new therapeutic targets, one project examining possible therapeutics and their impact on disease models of muscular dystrophy, and one project devoted to building tools necessary for human clinical trials in the muscular dystrophies.
Aim 1: Delineation of the cells that contribute to fibrosis and fat
Aim 2: Impact of genetic modifiers of inflammation and fibrosis on the cells involved in fibrosis
Aim 3: Modulation of fibrosis using therapeutics to decrease inflammatory and fibrotic responses and TGF-b1 signaling on the DBA background
Identification of Modifiers of Fibrosis Based on Differential Genetic Backgrounds in Mice
MR Imaging of Failed Regeneration and Cardiopulmonary Function